Newron Pharmaceuticals S.p.A. (NWRN.SW)

CHF 6.46

(0.62%)

Net Debt Summary of Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.'s latest annual net debt in 2023 was 42.07 Million EUR , up 30.52% from previous year.
Newron Pharmaceuticals S.p.A.'s latest quarterly net debt in 2024 Q2 was 40.63 Million EUR , down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported annual net debt of 32.23 Million EUR in 2022, up 78.49% from previous year.
Newron Pharmaceuticals S.p.A. reported annual net debt of 18.06 Million EUR in 2021, up 37.54% from previous year.
Newron Pharmaceuticals S.p.A. reported quarterly net debt of 39.35 Million EUR for 2023 Q2, down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported quarterly net debt of 42.07 Million EUR for 2023 FY, up 30.52% from previous quarter.

Annual Net Debt Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Net Debt of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year	Net Debt	Net Debt Growth
2023	42.07 Million EUR	30.52%
2022	32.23 Million EUR	78.49%
2021	18.06 Million EUR	37.54%
2020	13.13 Million EUR	354.25%
2019	-5.16 Million EUR	81.22%
2018	-27.49 Million EUR	32.34%
2017	-40.64 Million EUR	4.56%
2016	-42.58 Million EUR	-20.69%
2015	-35.28 Million EUR	-99.7%
2014	-17.66 Million EUR	-4.05%
2013	-16.98 Million EUR	38.12%
2012	-27.44 Million EUR	-754.86%
2011	-3.21 Million EUR	60.31%
2010	-8.08 Million EUR	63.91%
2009	-22.4 Million EUR	44.48%
2008	-40.35 Million EUR	35.24%
2007	-62.32 Million EUR	15.39%
2006	-73.66 Million EUR	-348.9%
2005	-16.4 Million EUR	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	40.63 Million EUR	0.0%
2023 Q2	39.35 Million EUR	0.0%
2023 FY	42.07 Million EUR	30.52%
2023 Q4	42.07 Million EUR	0.0%
2022 Q2	25.58 Million EUR	0.0%
2022 FY	32.23 Million EUR	78.49%
2022 Q4	32.23 Million EUR	0.0%
2021 FY	18.06 Million EUR	37.54%
2021 Q4	18.06 Million EUR	0.0%
2021 Q2	15.54 Million EUR	0.0%
2020 Q4	13.13 Million EUR	0.0%
2020 FY	13.13 Million EUR	354.25%
2020 Q2	3.55 Million EUR	0.0%
2019 Q2	-2.69 Million EUR	0.0%
2019 Q4	-5.16 Million EUR	0.0%
2019 FY	-5.16 Million EUR	81.22%
2018 Q4	-27.49 Million EUR	0.0%
2018 FY	-27.49 Million EUR	32.34%
2018 Q2	-31.26 Million EUR	0.0%
2017 Q2	-40.24 Million EUR	0.0%
2017 FY	-40.64 Million EUR	4.56%
2017 Q4	-40.64 Million EUR	0.0%
2016 Q2	-29.91 Million EUR	0.0%
2016 Q4	-42.58 Million EUR	0.0%
2016 FY	-42.58 Million EUR	-20.69%
2015 Q4	-35.28 Million EUR	0.0%
2015 FY	-35.28 Million EUR	-99.7%
2015 Q2	-37.61 Million EUR	0.0%
2014 Q2	-21 Million EUR	0.0%
2014 FY	-17.66 Million EUR	-4.05%
2014 Q4	-17.66 Million EUR	0.0%
2013 Q4	-16.98 Million EUR	0.0%
2013 Q2	-20.14 Million EUR	0.0%
2013 FY	-16.98 Million EUR	38.12%
2012 Q2	-13.47 Million EUR	0.0%
2012 Q4	-27.44 Million EUR	0.0%
2012 FY	-27.44 Million EUR	-754.86%
2011 Q2	-8.01 Million EUR	0.0%
2011 FY	-3.21 Million EUR	60.31%
2011 Q4	-3.21 Million EUR	0.0%
2010 Q2	-12.86 Million EUR	0.0%
2010 FY	-8.08 Million EUR	63.91%
2010 Q4	-8.08 Million EUR	0.0%
2009 Q4	-22.4 Million EUR	0.0%
2009 FY	-22.4 Million EUR	44.48%
2008 FY	-40.35 Million EUR	35.24%
2007 FY	-62.32 Million EUR	15.39%
2006 FY	-73.66 Million EUR	-348.9%
2005 FY	-16.4 Million EUR	0.0%

Peer Net Debt Comparison of Newron Pharmaceuticals S.p.A.

Name	Net Debt	Net Debt Difference
Addex Therapeutics Ltd	-3.52 Million CHF	1294.981%
BB Biotech AG	304.39 Million CHF	86.177%
Basilea Pharmaceutica AG	116.11 Million CHF	63.763%
Evolva Holding SA	-5.83 Million CHF	820.657%
Idorsia Ltd	1.05 Billion CHF	96.025%
Kuros Biosciences AG	-8.69 Million CHF	584.2%
Molecular Partners AG	-183.23 Million CHF	122.963%
Relief Therapeutics Holding AG	-10.24 Million CHF	510.708%
Santhera Pharmaceuticals Holding AG	-5.3 Million CHF	892.709%